Trius Therapeutics, Inc. (Trius) is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for serious, life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications.
23/01/12Trius gets $5 mln payment for completing first phase 3 trial of tedizolid from Bayer
19/12/11Trius says late-stage trial for skin infection drug meets study endpoint
27/07/11Trius Therapeutics and Bayer sign collaborative agreement for Torezolid antibiotic rights
Recent Sector News
NanoViricides (OTCBB:NNVC), a development stage company creating special purpose nanomaterials for antiviral therapy, said Wednesday its cash position at the end of the first quarter was "sufficient to carry out its initial clinical trials of its first drug candidate."
Pressure BioSciences rallies on potential new method for screening GI system using core PCT technology
Pressure BioSciences, (OTCQB: PBIO), a company focused on developing its pressure cycling technology (PCT), says that researchers at Harvard Medical School have published a scientific paper describing a non-invasive method that could potentially screen for multiple diseases by gaining information about the gastrointestinal (GI) system using PCT and certain chemicals.
The research firm said it expects the company to be profitable in 2014 as it increases its market share. The company "is poised for substantial growth with the aggressive commercialization and increased distributor agreements, of its Barocycler product portfolio, new offerings in its pipeline and promising new markets for its existing technology."
Shares of Pressure BioSciences (OTCQB:PBIO), a life sciences company focused on developing its pressure cycling technology (PCT), have been described as "deeply undervalued", according to Zacks Investment Research analyst Grant Zeng, when looking at the company's fundamentals.
Pressure BioSciences (OTCQB:PBIO), a life science company developing pressure cycling technology, or PCT, said that recent research has shown that PCT-based sample preparation methods have yielded improved quality and efficiency of test results.
NanoViricides (OTCBB:NNVC) saw its shares surge over seven per cent Wednesday, after announcing that president Anil Diwan will lead section 1 of the Symposium on Nanomedicines: Charting a Roadmap to Commercialization, called “Designing Nanomedicines”.
Investors interested in Trius Therapeutics recently viewed
- African Medical Investments (AIM: AMEI) Capital Appreciation through Private Healthcare in Africa
- NanoViricides (OTCBB: NNVC) Anti-virals for the 21st Century
- Consegna Group (ASX: CGP) A vehicle to the China & North Asian pharmaceutical markets
- HealthLinx (ASX: HTX) HealthLinx will be recognised as a leader in delivering diagnostic applicat
- Pulse Health Group (ASX: PHG) Care / Commitment / Community